Physician profile
Michael Merced
NPI 1689108185
$1,227.34
in general payments reported to CMS, 2019-2025
16 companies · $35.56 in 2025
The $35.56 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2021: $504 · 2022: $483 · 2023: $13.01 · 2024: $66.36 · 2025: $35.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $114.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $238.82 | 2019-2022 | |
| Novo Nordisk INC | $183.08 | 2021-2025 | Wegovy |
| Amgen INC. | $133.38 | 2021-2022 | |
| Amarin Pharma, INC. | $113.92 | 2021-2022 | |
| Dexcom, INC. | $92.73 | 2022-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $72.68 | 2021-2023 | Mounjaro |
| Mannkind Corporation | $69.32 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $56.08 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $55.64 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $55.31 | 2021-2024 | Gardasil 9, Capvaxive, Gardasil |
| Abbott Laboratories | $45.57 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $45.00 | 2021 | |
| Glaxosmithkline, LLC. | $24.76 | 2022 | |
| Phadia US INC. | $14.67 | 2022 | |
| Horizon Therapeutics Plc | $13.54 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $12.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Merced listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.